Ki Chung is an Oncology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
120 Dillon Dr
Spartanburg, SC 293071018
Telephone
864-699-5700Registry record last updated 31 Jan 2018.
Clinical trials
- Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Sponsor: Prisma Health-Upstate
- Prospective Registration of Head and Neck Cancer
Sponsor: Samsung Medical Center
- Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)
Sponsor: US Oncology Research
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
81 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202510 payments
- AstraZeneca Pharmaceuticals LPProgram year202511 payments
- Novartis Pharmaceuticals CorporationProgram year202514 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
24.7%Kinase inhibitor7.4%Calquence19%Verzenio17%Jakafi16%Ibrance16%Imatinib Mesylate16%Sprycel16%Part D<11 patientsAromatase Inhibitor6.2%Anastrozole70%Letrozole30%Part D<11 patients+ 5 more classes in this area
Nervous system
24.3%Opioid Agonist13.3%Oxycodone Hcl40%Fentanyl15%Morphine Sulfate14%Morphine Sulfate Er11%Oxycodone-Acetaminophen11%Tramadol Hcl8%Part D<11 patientsBenzodiazepine5.9%Lorazepam63%Alprazolam37%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
15.3%Serotonin-3 Receptor Antagonist8.2%Ondansetron Hcl77%Ondansetron Odt23%Part D<11 patientsCorticosteroid2.5%Prednisone100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2019–2025 per NIH RePORTER. The latest:
- NCORP of the Carolinas (Greenville Health System NCORP)
Prisma Health - Upstate
FY2025$1,363,029UG1CA189972 - NCORP of the Carolinas (Greenville Health System NCORP)
Prisma Health - Upstate
FY2024$1,363,028UG1CA189972 - NCORP of the Carolinas (Greenville Health System NCORP)
Prisma Health - Upstate
FY2023$1,372,191UG1CA189972
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”